How is semaglutide dosed?
Semaglutide is dosed once weekly under two injectable FDA labels, Ozempic and Wegovy: both start at 250 mcg, Ozempic rising to a 2,000 mcg (2 mg) maximum and Wegovy over 16 weeks to a 2,400 mcg (2.4 mg) maintenance dosage, with an optional 7,200 mcg (7.2 mg) (7.2 mg) for weight. Their missed-dose windows differ; this page sets the two side by side, with the trials neither label cites.
Topic: Comparing semaglutide’s two injectable FDA labels
Audience: Anyone comparing a semaglutide dosing figure against its actual label source
Reading time: 8–10 minutes
Not affiliated with Novo Nordisk
Prof. Peptide is not affiliated with, endorsed by, or sponsored by Novo Nordisk. Ozempic and Wegovy are registered trademarks of Novo Nordisk A/S. This page reports what Novo Nordisk’s own prescribing information and FDA’s own publications state for both labels; it does not sell, ship, or recommend either branded product. Both labels describe a prescription pen or prefilled syringe, dispensed by a pharmacy — research-grade semaglutide, the material Prof. Peptide’s vendors sell, is neither of those products, described fully in the compounding section below.
What semaglutide is
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist, manufactured by Novo Nordisk. It has two injectable FDA-approved labels covering different indications: Ozempic (type 2 diabetes, cardiovascular risk, chronic kidney disease) and Wegovy (weight reduction and cardiovascular risk reduction, without a type 2 diabetes requirement). A third brand, Rybelsus, is an oral tablet with its own separate label and schedule — outside the injection-to-injection comparison this page focuses on, and compared with the injections in semaglutide pills vs injection. Ozempic and Wegovy share the same active ingredient and the same manufacturer, but each sets its own escalation schedule, cites its own trials, and carries its own missed-dose rule.
Each injectable label is set out in full on its own page — how Ozempic is dosed and how Wegovy is dosed. This page puts the two in one table; the semaglutide profile covers the mechanism and the wider trial evidence.
Ozempic vs. Wegovy: the label schedules, compared
Novo Nordisk, OZEMPIC (semaglutide) injection prescribing information, DailyMed setid adec4fd2-6858-4c99-91d4-531f5f2a2d79, effective May 19, 2026; Novo Nordisk, WEGOVY (semaglutide) injection and tablets prescribing information, DailyMed setid ee06186f-2aa3-4990-a760-757579d8f77b, effective June 18, 2026. Each brand’s own adverse-event figures sit directly under that brand’s dosage table, at its own reported dose, rather than in a separate section.
Ozempic
full Ozempic dosing guide- Indication
- Type 2 diabetes: glycemic control; cardiovascular risk reduction in adults with established cardiovascular disease; and reducing the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease.
- Starting dosage
- 250 mcg once weekly for 4 weeks (initiation, not for glycemic control)
- Escalation
- 500 mcg after 4 weeks; 1,000 mcg (1 mg) after at least 4 more weeks if additional glycemic control is needed
- Maintenance
- 1,000 mcg (1 mg) once weekly is the label's chronic-kidney-disease maintenance dosage specifically; otherwise no separate maintenance step is named beyond the escalation path.
- Maximum dosage
- 2,000 mcg (2 mg) once weekly, reached only after at least 4 weeks each at 500 mcg and 1,000 mcg (1 mg)
- Missed-dose window
- Administered within 5 days of the missed dose; beyond that, the missed dose is skipped and the regular weekly schedule resumes.
- Boxed warning
- Thyroid C-cell tumors; the label states their relevance to people has not been determined.
- Trials cited in the label
- Monotherapy trial (NCT02054897), SUSTAIN 6 (NCT01720446), FLOW (NCT03819153).
Top adverse reactions reported
Across trial doses (500/1,000 mcg (1 mg), N=260/261): nausea 15.8%/20.3%, vomiting 5%/9.2%, diarrhea 8.5%/8.8% — versus 6.1%, 2.3%, and 1.9% on placebo.
Wegovy (injection)
full Wegovy dosing guide- Indication
- Weight reduction (with a reduced-calorie diet and increased activity) in adults with obesity, or overweight with a weight-related condition, reducing cardiovascular risk in adults with established cardiovascular disease and obesity or overweight — no type 2 diabetes requirement — and noncirrhotic MASH. A separate oral-tablet formulation exists with its own schedule, not covered in this comparison.
- Starting dosage
- 250 mcg once weekly, weeks 1–4
- Escalation
- 500 mcg (weeks 5–8), 1,000 mcg (1 mg) (weeks 9–12), 1,700 mcg (1.7 mg) (weeks 13–16) — four steps versus Ozempic's two
- Maintenance
- 2,400 mcg (2.4 mg) (recommended) or 1,700 mcg (1.7 mg) once weekly from week 17; if 2,400 mcg (2.4 mg) is tolerated ≥ 4 weeks and additional weight reduction is clinically indicated, the label permits escalation to a 7,200 mcg (7.2 mg) maximum — a dose Ozempic's label has no equivalent of.
- Maximum dosage
- 7,200 mcg (7.2 mg) once weekly for weight reduction (optional, beyond the 2,400 mcg (2.4 mg) recommended dosage); no escalation past 2,400 mcg (2.4 mg) described for cardiovascular risk reduction specifically
- Missed-dose window
- Administered as soon as possible only if the next dose is more than 2 days away; otherwise the missed dose is skipped. Two or more consecutive missed doses restart the escalation from a lower dosage — a shorter window and a stricter restart rule than Ozempic's label.
- Boxed warning
- Thyroid C-cell tumors; the label states their relevance to people has not been determined.
- Trials cited in the label
- Study 1 (NCT03574597, publicly known as SELECT), Study 2 (NCT03548935).
Top adverse reactions reported
At the 2,400 mcg (2.4 mg) dose: nausea 44%, diarrhea 30%, vomiting 24%, constipation 24% — versus 16%, 16%, 6%, and 11% on placebo.
Both labels start at the same 250 mcg once-weekly dosage, and that is where the similarity mostly ends. Ozempic’s label reaches its 2,000 mcg (2 mg) maximum in two steps, each requiring at least 4 weeks; Wegovy’s label takes four steps over 16 weeks to reach a 2,400 mcg (2.4 mg) recommended maintenance dosage, with an optional fifth step to a 7,200 mcg (7.2 mg) maximum that Ozempic’s label has no equivalent of at all. The missed-dose rules are not interchangeable either: Ozempic allows 5 days before a dose is skipped, while Wegovy allows only 2 days and additionally requires restarting the escalation at a lower dosage after two or more consecutive missed doses — a rule with no parallel on Ozempic’s label. A reader applying one label’s missed-dose window to the other brand would be following the wrong rule.
Trials that add something neither label states
Each label cites its own trial program — the monotherapy trial, SUSTAIN 6, and FLOW for Ozempic; Study 1 through Study 10 (publicly known as STEP) for Wegovy. Two published trials sit outside both labels entirely and answer questions neither one does:
SURMOUNT-5 (NCT05822830)
72-week, randomized, open-label, head-to-head trial
Arms: 751 adults with obesity or overweight, without type 2 diabetes, randomized to semaglutide (maximum tolerated dose, 1,700 or 2,400 mcg, 1.7 or 2.4 mg) or tirzepatide (maximum tolerated dose, 10,000 or 15,000 mcg, 10 or 15 mg), both once weekly subcutaneous.
Endpoint reported: Body weight change at week 72: 13.7% with semaglutide vs. 20.2% with tirzepatide. GI-related discontinuation was also reported higher with semaglutide than tirzepatide in this trial. Neither Ozempic’s nor Wegovy’s own Clinical Studies section cites this trial — it directly compares semaglutide against a different compound, outside what either label’s own trial program is designed to show.
Attributed — published (N Engl J Med, 2025) and registered with a checkable NCT number.
STEP 4 (NCT03548987)
Randomized-withdrawal trial: 20-week open-label semaglutide run-in, then 48-week double-blind semaglutide vs. placebo
Arms: 902 adults with overweight or obesity entered the run-in; those reaching the 2,400 mcg (2.4 mg) (2.4 mg) target dose were randomized 2:1 to continue semaglutide or switch to placebo from week 20.
Endpoint reported: Among participants switched to placebo, mean weight regain was 11.6% of body weight over the following 48 weeks; those continuing semaglutide maintained their loss. Neither label’s escalation table addresses what happens to the dose response after stopping — this trial does.
Attributed — published (JAMA, 2021) and registered with a checkable NCT number.
How do clinics dose compounded semaglutide?
Clinics prescribing compounded semaglutide publish weekly titrations that follow the Wegovy ladder or sit below it: most start at 200 to 350 mcg a week and step up every 2 to 4 weeks. One gives 250 mcg, then 500 mcg (months 1–2), 1,000 mcg (1 mg) then 1,700 mcg (1.7 mg) (months 3–4), and 1,700 or 2,400 mcg (1.7 or 2.4 mg) from month 5, a table it says follows the approved formulation. Another starts at 200 mcg (8 units) and changes the dose every two weeks, through 300 to 850 mcg, to a 1,200 mcg (1.2 mg) (1.2 mg) maximum. A 503A pharmacy gives 250 mcg for 4 weeks, then 500 mcg and 1,000 mcg (1 mg) (1 mg). These are the clinics’ own schedules, set out with their sources on the semaglutide profile.
One clinic states that its safety information for compounded semaglutide is based on FDA labeling and that compounded semaglutide “has not been separately studied.” No published research-grade dosing protocol differs from these clinic and label schedules.
Compounding and research-grade semaglutide
Neither Ozempic’s nor Wegovy’s prescribing information mentions compounding — the word does not appear in either label. Everything in the comparison above describes a prescription drug product, manufactured by Novo Nordisk and dispensed by a pharmacy against a prescription.
Research-grade semaglutide, of the kind sold by the vendors Prof. Peptide tracks elsewhere on this site, is neither branded product described above nor a pharmacy-compounded version of either. It is sold labeled for research use, not for human administration, and it is not dispensed against a prescription.
Separately from either branded label, FDA has published its own position on compounded semaglutide. Its April 1, 2026 statement on compounding, once the national GLP-1 supply stabilized, describes the conditions under which a compounded drug can lawfully be exempt under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act, and states FDA’s position that a compounded product is treated as an unlawful copy of a commercially available drug when it shares the same active ingredient, a similar or easily substitutable strength, and the same route of administration — unless a prescriber documents a significant difference for an individual patient.
On April 30, 2026, FDA announced it is proposing to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list entirely, stating it “did not identify a clinical need for outsourcing facilities to compound semaglutide, tirzepatide, and liraglutide from bulk drug substances.” The public comment period on that proposal closed, and FDA has not published a final determination.
FDA also writes that the salt forms some compounders sell, semaglutide sodium and semaglutide acetate, are different active ingredients from those in the approved drugs, and that it is “not aware of any lawful basis for their use in compounding.” It reports adverse events, some requiring hospitalization, linked to dosing errors with compounded injectable semaglutide.
None of this changes what either label above states, and none of it describes Prof. Peptide’s vendors as compounding pharmacies — they are not. It is published here, at the compound level rather than under either brand alone, because a reader comparing research-grade semaglutide against the approved product should see, in one place, that both labels are governed by different rules from the research-grade material, and that the regulatory status of compounded semaglutide is itself unsettled.
How this page differs from the brand guides and the profile
How Ozempic is dosed and how Wegovy is dosed each read one label in full depth — a complete escalation table, boxed warning quoted verbatim, and a full adverse-reaction table, with a standalone warnings section and Wegovy’s guide additionally covering its oral-tablet form. Neither compares its own figures against the other brand’s in a table; each treats the other only in passing. This page is the one place both injectable schedules, both missed-dose windows, and both boxed-warning wordings sit in the same table, with adverse events placed next to each brand’s own dose rather than in a separate section.
The semaglutide profile is a different kind of page again: it covers the molecule’s mechanism and the published trial evidence across all three brands (including Rybelsus), without reading either injectable label’s escalation table, missed-dose rule, or ADR table in the detail either brand guide or this page does.
FAQ
Is semaglutide the same as Ozempic or Wegovy?
Do Ozempic and Wegovy use the same dosing schedule?
Which trials does each label cite?
How do clinics dose compounded semaglutide?
Is research-grade or compounded semaglutide the same as Ozempic or Wegovy?
References
- Novo Nordisk. OZEMPIC (semaglutide) injection, for subcutaneous use — prescribing information. DailyMed, setid adec4fd2-6858-4c99-91d4-531f5f2a2d79, effective 2026-05-19. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79
- Novo Nordisk. WEGOVY (semaglutide) injection and tablets, prescribing information. DailyMed, setid ee06186f-2aa3-4990-a760-757579d8f77b, effective 2026-06-18. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
- Aronne LJ, Horn DB, le Roux CW, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5). N Engl J Med. 2025. ClinicalTrials.gov NCT05822830. https://clinicaltrials.gov/study/NCT05822830
- ClinicalTrials.gov. Effect and Safety of Semaglutide 2.4 mg Once-weekly in Subjects With Overweight or Obesity Who Have Reached Target Dose During Run-in Period (STEP 4), NCT03548987. https://clinicaltrials.gov/study/NCT03548987
- U.S. Food and Drug Administration. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize. Drug Alerts and Statements, 2026-04-01. https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize
- U.S. Food and Drug Administration. FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List. Press Announcements, 2026-04-30. https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list
- U.S. Food and Drug Administration. FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. Content current as of October 1, 2026; read November 6, 2026. fda.gov
- Clinic sources for the compounded-semaglutide schedules, each read November 3–6, 2026: Trimi Health (trytrimi.com/treatments/semaglutide), Noom GLP-1Rx dosing guide (noom.com), Empower Pharmacy (empowerpharmacy.com), Henry Meds (henrymeds.com) and Ivím Health’s compounded-semaglutide safety information (ivimhealth.com). The full record, with links, is on the semaglutide profile.
Affiliate disclosure: Prof. Peptide earns a commission on purchases and sign-ups made through its links and codes, at no extra cost to the buyer. Commissions never decide which vendors are listed, how they are ranked or verified, or what Prof. Peptide concludes.
Related pages
- SemaglutideSemaglutide in people: STEP weight-loss trials, SELECT, SUSTAIN-6 and FLOW outcome trials, the Wegovy and Ozempic label doses, side-effect rates from the label, and…
- Retatrutide Dosage: Clinic Doses and Phase 3 Trial DosesRetatrutide dosage: what clinics publish (weekly injections of 2,000 to 12,000 mcg, 2 to 12 mg), the doses its Phase 2 and peer-reviewed Phase 3 trials used, side…
- Semaglutide Half-Life Calculator — Accumulation at ~1 WeekSemaglutide Half-Life Calculator — Accumulation at ~1 Week.
- Survodutide Dosage: Phase 3 Trial Doses and What Clinics ReportSurvodutide dosage: the 3,600 and 6,000 mcg (3.6 and 6 mg) weekly doses of its phase 3 SYNCHRONIZE trials, how the dose was raised, side effects at each dose, what…
- Guides — Practical Peptide Research ReferencesPractical reference guides for peptide research — injection technique, reconstitution math, syringe sizing, and research fundamentals.
- Semaglutide Calculator: Reconstitution & DosageSemaglutide reconstitution and dosage math — vial size, BAC water and syringe units, worked for real vendor vial sizes.
Checked and updated
